Botox vs. Combination Drug Therapy for Women with Overactive Bladder

Medications and intradetrusor injections of onabotulinumtoxinA (Botox) are treatment options for women with overactive bladder who don’t respond adequately to behavioral approaches or pelvic-floor physical therapy. For this study, researchers identified 66 symptomatic women (mean age, 60) who had documented detrusor overactivity that responded inadequately to monotherapy with either an antimuscarinic agent or a β3-agonist. Participants were randomized to receive either combination drug therapy (the antimuscarinic agent solifenacin plus the β3-agonist mirabegron) or onabotulinumtoxinA injections. Patients with neurological disorders or pelvic floor structural abnormalities were excluded.